GnRHaGonadotrophin Releasing Hormone Agonistic Analogue
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Administration of GnRHa is an attractive option for fertility preservation in BC patients because it is noninvasive, easy to administer, does not require the usage of assisted reproductive technologies, and does not require delay in chemotherapy initiation (9).
Considering the increasing prevalence of obesity all over the world and the higher prevalence of PP in obese people compared to the normal population (14-17), the importance of the effects of GnRHa treatment used for PP on body weight is increasing day by day.
At present, the medications used in the treatment of EM include GnRHa, selective progesterone receptor modulators, selective estrogen receptor modulators, aromatase inhibitors, immunomodulatory, and antiangiogenic agents.
In this retrospective cohort study, for the patients who had GnRHa treatment with ICPP diagnosis, GV records obtained at three month periods were investigated from the beginning until the end of treatment.
Patients in the study group (group A) received a single dose of 3.75 mg GnRHa-leuprolide acetate subcutaneously within 48 h after surgery, whereas the control group (group B) did not receive GnRHa. The injection leuprolide acetate (injection Leuprodex depot) was given free of cost.
2- Cryopreservation of all embryos: Although there is inadequate evidence in support of routine cryopreservation in a Cochrane Review with two randomized controlled trials, recent studies have reported that the most effective method in preventing OHSS is the use of a GnRHa trigger and then cryopreservation of all embryos.
Despite different growth patterns, GnRHa therapy was effective in both groups decreasing basal gonadotropin and oestradiol/testosterone levels (Table 3) and reducing the signs of pubertal progression (Figure 1).
Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment.
One of the risks for puberty suppression with a gonadotropin-releasing hormone agonist (GnRHa)--such as leuprolide is reduced bone mineral density (BMD).
O tratamento da puberdade precoce verdadeira se faz por meio do bloqueio desta com analogos do GnRH (GnRHa).
When bass (Dicentrarchus labrax L.) and white bass (Morone chrysops) were injected with gonadotropin- releasing hormone antagonist (GnRHa) and then exposed to higher temperature, enhanced milt production was observed.